MedTrace Logo

Study of the Concentration-effect Relationship of Nivolumab in Patients With Kidney or Lung Cancer

NCT03433534 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 64

Last updated 2019-11-12

No results posted yet for this study

Summary

To assess the relationship between progression free survival of patients treated with nivolumab for metastatic non small cell lung carcinoma or a metastatic renal cell carcinoma and nivolumab blood concentration.

Collection of standard data prospectively.

Conditions

Interventions

OTHER

Pharmacokinetic of Nivolumab

Nivolumab residual concentration is measured 14 days after administration of nivolumab 3 mg/kg as an intravenous infusion just before the new administration.

Sponsors & Collaborators

  • University Hospital, Tours

    lead OTHER

Principal Investigators

  • Claude Linassier · University Hospital, Tours

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-29
Primary Completion
2018-12-21
Completion
2018-12-21

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03433534 on ClinicalTrials.gov